A trial of Bioheart's adipose-derived, autologous stem cell therapy for congestive heart failure: the ANGEL trial.

Trial Profile

A trial of Bioheart's adipose-derived, autologous stem cell therapy for congestive heart failure: the ANGEL trial.

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 13 Oct 2014

At a glance

  • Drugs Adipose-derived autologous stem cell therapy Bioheart (Primary)
  • Indications Heart failure
  • Focus Adverse reactions
  • Acronyms ANGEL
  • Sponsors U.S. Stem Cell
  • Most Recent Events

    • 13 Oct 2014 Preliminary 12-month data reported in a Bioheart media release.
    • 05 May 2014 Top-line results for quality of life and 4-year safety reported in a Bioheart media release.
    • 30 Apr 2014 Six-month results have been reported in a Bioheart media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top